title: Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
abstract: BACKGROUND
  In vitro and animal studies have shown that moxifloxacin-containing combinations may improve the bactericidal efficacy of antituberculosis regimens.
  
  
  METHODS
  We measured the decline in the sputum viable count of 13 patients who were given a combination of moxifloxacin 400 mg daily and isoniazid 300 mg daily.
  
  
  RESULTS
  The time required to reduce the viable count by 50% (vt50) was 0.38 days (95% CI -0.03-0.78 days, SEM 0.13) and the mean early bactericidal activity (EBA) was 0.60 log10 cfu/day (95% CI 0.23-0.97, SEM 0.14). This compares with the vt50 calculated for isoniazid and moxifloxacin alone in the same population of 0.48 and 0.88 days, respectively. The EBA values for isoniazid and moxifloxacin alone were 0.77 and 0.53 log10 cfu/day, respectively.
  
  
  CONCLUSIONS
  The combination of moxifloxacin and isoniazid is not antagonistic, but the combination does not significantly enhance bactericidal activity above that of isoniazid alone.
authors.affiliation: Centre for Medical Microbiology, Hampstead Campus, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK. s.gillespie@medsch.ucl.ac.uk
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Gillespie
authors.forename: Roly D
authors.initials: RD
authors.lastname: Gosling
authors.forename: Leonard
authors.initials: L
authors.lastname: Uiso
authors.forename: Noel E
authors.initials: NE
authors.lastname: Sam
authors.forename: Esther G
authors.initials: EG
authors.lastname: Kanduma
authors.forename: Timothy D
authors.initials: TD
authors.lastname: McHugh
mesh_terms: D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin; D007538:Isoniazid